Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astex Aims To Make Cancer Drug Resistance Futile

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

“Using our drugs, we’re trying to facilitate the old drugs or help them work better longer,” Astex’s Lyons said. Astex, AstraZeneca and Novartis all presented data on compounds from Astex’s fragment-based drug discovery platform at the recent American Association for Cancer Research meeting in Washington, D.C.

Advertisement

Related Content

Deals Of The Week: Hunting For Dengue Fever Drugs Amid Climate Change
Astex Finds A Suitable Home As Otsuka Subsidiary
Astex Finds A Suitable Home As Otsuka Subsidiary
Cancer Research UK’s CRT: A Bridge Between Big Pharma And Academia
Epigenetics At The Epicenter Of Oncology Drug Discovery At AACR
Panel: Oncology Business Models Determined By Capital And Culture
Dacogen Leukemia Indication Needs New Clinical Trial, FDA Tells Eisai
SuperGen Buys U.K.'s Astex, Building Cash-Rich Oncology Play

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS005427

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel